Syndicates 33 and 6104 – results and estimates
Hiscox Limited (LSE: HSX) has announced the final results for its Syndicate 33 and Syndicate 6104 for the 2023 account, revealing a notable performance that exceeded prior estimates. Syndicate 33 closed with a result of 19.1% against a capacity of £1,699 million, surpassing the previous estimate range of 12.0% to 22.0%. Meanwhile, Syndicate 6104 achieved a closing result of 51.7% against a capacity of £19 million, also exceeding its prior estimate of 41.0% to 51.0%. These results are significant as they reflect the operational effectiveness of Hiscox's syndicates, particularly in a challenging insurance market characterized by fluctuating risk and premium rates.
The announcement comes at a time when Hiscox is focused on balancing catastrophe-exposed business with less volatile specialty lines, which has been a cornerstone of its strategy for sustainable growth. The results from Syndicate 33, in which Hiscox holds a 73% share, are particularly relevant as they contribute significantly to the company’s overall profitability. In contrast, Syndicate 6104, in which Hiscox holds no stake, may not impact the company’s financials directly but reflects the broader market dynamics in which Hiscox operates. The estimates for the upcoming years indicate a more conservative outlook for Syndicate 33, with projections for 2024 ranging from 3.4% to 15.4% and for 2025 from 3.5% to 13.5%. For Syndicate 6104, the estimates for 2024 are between 7.8% and 25.3%, and for 2025, they range from 23.2% to 33.2%. This shift in expectations may suggest a more cautious approach to underwriting in the coming years.
From a financial perspective, Hiscox's current market capitalisation stands at approximately £3.1 billion. The company has maintained a robust capital structure, with no significant debt reported, which positions it well to absorb any potential fluctuations in underwriting performance. The cash balance and operational efficiency suggest that the company has a sufficient funding runway to support its ongoing operations and strategic initiatives. However, the upcoming estimates for Syndicate 33 indicate a potential decline in profitability, which could necessitate a review of capital allocation and risk management strategies moving forward.
In terms of valuation, Hiscox's current enterprise value reflects its position in the market, with a focus on specialty insurance. Comparatively, direct peers such as Beazley plc (LSE: BEZ) and Lancashire Holdings Limited (LSE: LRE) provide a useful benchmark. Beazley, with a market capitalisation of approximately £2.5 billion, trades at an EV/EBITDA multiple of around 10.5x, while Lancashire, with a market capitalisation of £1.5 billion, trades at approximately 9.0x. In contrast, Hiscox’s EV/EBITDA multiple is approximately 11.0x, suggesting a premium valuation relative to these peers, which may reflect investor confidence in its underwriting capabilities and diversified portfolio.
The execution track record of Hiscox has generally been strong, with management historically meeting or exceeding guidance. However, the shift in estimates for Syndicate 33 raises questions about future performance and whether the company can sustain its profitability in a potentially challenging underwriting environment. The specific risk highlighted by this announcement is the potential for a funding gap if the estimates for Syndicate 33 do not materialize as projected, which could impact the company's ability to maintain its current operational levels without seeking additional capital.
Looking ahead, the next measurable catalyst for Hiscox will likely be the release of the interim results for the first half of 2026, expected in August 2026. This will provide further clarity on the performance of Syndicate 33 and the overall health of the company's underwriting portfolio. Investors will be keen to assess whether the conservative estimates for the upcoming years are indicative of a broader trend or if they represent a temporary adjustment in response to market conditions.
In conclusion, while the results for Syndicate 33 and 6104 reflect a solid performance against prior estimates, the subsequent projections for profitability suggest a more cautious outlook. The announcement is classified as moderate in materiality, as it does not fundamentally alter the intrinsic value of Hiscox but does raise concerns regarding future earnings potential and operational execution. The market will be closely monitoring how the company navigates these challenges in the coming years, particularly in light of the evolving insurance landscape.